Market Cap
$2.5B
SUPN
SUPERNUS PHARMACEUTICALS, INC.
$42.30 ▲ +0.28%
Prev close $42.18Market cap$2.5B
ConsensusStrong Buy
12-mo target$61.75 (+46.0%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (7 insiders)High Impact Filing (7/10)26 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SUPN right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (82%)
Inst. Holders
50 funds
Inst. Value
$2.1B
Inst. Activity
26 buys / 18 sells
Insider Activity
$0.00 buy / $8.5M sell
Insider Net $
-$8.5M
SEC Reports
20
Price chart 30d -3.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 clinical_trial_readout
Sep 11, 2026 SEC T-90d Trial Readout: BIS-001ER (Phase 2)
Trial: BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures Sponsor: Supernus Pha
Supernus Pharmaceuticals is merging with Indivior in an all-stock merger of equals. Each Supernus share will convert int
DEFM14A — Impact 7/10
Aug 12, 2026 Insider
DEC TIMOTHY C acquired via exercise 1,250 shares
Senior Vice-President & CFO
Aug 12, 2026 Insider
DEC TIMOTHY C surrendered for taxes 604 shares
Senior Vice-President & CFO @ $46.57 ($28.1K)
Aug 12, 2026 Insider
Aug 3, 2026 SEC Khattar Jack A. acquired via exercise 29,849 shares
President, CEO
Supernus and Indivior announced an all-stock merger of equals to create a combined CNS biopharma company with ~$2.2B in
DEFA14A, 425 — Impact 7/10
Supernus Pharmaceuticals and Indivior have entered into an all-stock merger of equals, announced via employee communicat
8-K — Impact 7/10
Jul 20, 2026 Event
US Worldmeds Partners, LLC v. Supernus Pharmaceuticals, Inc.
Court ruling (delsuperct) — Docket: N25C-07-121 KMM CCLD
Analyst ratings buy % -1.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
82% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 9, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Aug 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Jul 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Jun 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% |
Price targets
Where 4 covering analysts think SUPN trades over the next 12 months.
$61.75 +46.0% upside Strong Buy
Current$42.30 Low$55.00 Median$62.50 High$67.00 4 analysts
$55.00$67.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 8 bullish, 0 bearish, 2 mixed, 10 neutral · avg impact 5.0/10.
MIXEDDEFM14A7/10
Supernus Pharmaceuticals is merging with Indivior in an all-stock merger of equals. Each Supernus sh
Sep 11, 2026
BULLISHDEFA14A, 4257/10
Supernus and Indivior announced an all-stock merger of equals to create a combined CNS biopharma com
Aug 3, 2026
BULLISH8-K7/10
Supernus Pharmaceuticals and Indivior have entered into an all-stock merger of equals, announced via
Aug 3, 2026
BULLISHDEFA14A, 425, 8-K8/10
Supernus Pharmaceuticals has entered into a definitive agreement to merge with Indivior Pharmaceutic
Aug 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Clinical Trial
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Oct 1, 2026
clinical_trial_readout
T-90d Trial Readout: BIS-001ER (Phase 2)
Trial: BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures Sponsor: Supernus Pharmaceuticals, Inc. Phase: Phase 2 | Status: ACTIVE
Sep 2, 2026
other
Supernus Pharmaceuticals to Participate in September Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing an
Aug 31, 2026
contract
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated am
Aug 4, 2026
earnings_calendar
SUPN Q2 2026 Earnings Scheduled — 2026-08-04
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.61 | $0.61–$0.62 | 1.2% | -7.8% | 0↑ 2↓ | $0.2B | 2 |
| Next Q | $1.08 | $0.90–$1.27 | 23.0% | +41.5% | 2↑ 0↓ | $0.2B | 2 |
| Current FY | $2.56 | $2.48–$2.65 | 7.1% | +3.1% | 1↑ 1↓ | $0.9B | 2 |
| Next FY | $4.46 | $4.37–$4.55 | 73.9% | +2.7% | 1↑ 1↓ | $1.4B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.615 | — |
| 7d ago | $0.663 | -0.048 |
| 30d ago | $0.667 | -0.052 |
| 60d ago | $0.667 | -0.052 |
| 90d ago | $0.705 | -0.090 |
Institutional ownership
Which big funds own SUPN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.1B total value (46,072,587 shares) as of 2026-Q2. Top holders: BlackRock,, MILLENNIUM, VANGUARD. Net buying activity: 26 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 9,350,046 | $434.9M | 20.3% | — |
| MILLENNIUM MANAGEMENT LLC | 3,853,212 | $179.2M | 8.4% | ADD +25.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,305,429 | $153.7M | 7.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,516,721 | $117.1M | 5.5% | — |
| STATE STREET CORP | 2,459,828 | $114.4M | 5.3% | — |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2,378,329 | $110.6M | 5.2% | — |
| DIMENSIONAL FUND ADVISORS LP | 2,078,090 | $96.7M | 4.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,570,088 | $73.0M | 3.4% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,478,180 | $68.8M | 3.2% | — |
| LOOMIS SAYLES & CO L P | 1,475,192 | $68.6M | 3.2% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | ADD | 498,198 | 922,166 | +85.1% | $42.9M |
| Woodline Partners LP | ADD | 448,996 | 708,276 | +57.7% | $32.9M |
| Aberdeen Group plc | ADD | 275,561 | 453,206 | +64.5% | $21.1M |
| SCHRODER INVESTMENT MANAGEMENT GROUP | DOUBLED | 176,076 | 368,017 | +109.0% | $17.2M |
| Freestone Grove Partners LP | TRIM | 641,319 | 316,398 | -50.7% | $14.7M |
| FMR LLC | ADD | 209,370 | 309,091 | +47.6% | $14.4M |
| Man Group plc | DOUBLED | 74,992 | 156,422 | +108.6% | $7.3M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 61,983 | 148,579 | +139.7% | $6.9M |
| FIRST TRUST ADVISORS LP | DOUBLED | 46,627 | 140,207 | +200.7% | $6.5M |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 72,430 | 115,125 | +58.9% | $5.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net -$8.5M — $0.00 bought, $8.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | DEC TIMOTHY C | Senior Vice-President & CFO | EXERCISE | 1,250 | — | — |
| Aug 12, 2026 | DEC TIMOTHY C | Senior Vice-President & CFO | TAX W/H | 604 | $46.57 | $28.1K |
| Aug 12, 2026 | Khattar Jack A. | President, CEO | EXERCISE | 29,849 | — | — |
| Aug 12, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | EXERCISE | 2,500 | — | — |
| Aug 12, 2026 | Rubin Jonathan | SVP, Chief Medical Officer | TAX W/H | 363 | $46.57 | $16.9K |
| Aug 12, 2026 | Bhatt Padmanabh P. | Sr. VP of IP, CSO | TAX W/H | 1,158 | $46.57 | $53.9K |
| Aug 12, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | EXERCISE | 1,650 | — | — |
| Aug 12, 2026 | Mottola Frank | SVP, Chief Tech. Ops. Officer | TAX W/H | 797 | $46.57 | $37.1K |
| Aug 12, 2026 | Rubin Jonathan | SVP, Chief Medical Officer | EXERCISE | 750 | — | — |
| Aug 12, 2026 | Khattar Jack A. | President, CEO | TAX W/H | 12,642 | $46.57 | $588.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SUPN.
Shares short
4,989,421
Settlement Sep 15, 2026
Change vs prior
+6.8%
Semi-monthly cycle
Days to cover
8.7
At avg daily volume
Of shares outstanding
≈8.6%
Estimate — not % of float
All SUPN filing & press-release reports (20)
- DEFM14A reportSep 11, 2026
- DEFA14A, 425 reportAug 3, 2026
- 8-K reportAug 3, 2026
- DEFA14A, 425, 8-K reportAug 3, 2026
- 8-K reportAug 3, 2026
- 8-K reportAug 3, 2026
- DEFA14A, 425 reportAug 3, 2026
- PRESS-RELEASE reportJul 22, 2026
- 8-K reportJul 22, 2026
- COURT-RULING reportJul 21, 2026
- COURT-RULING reportJul 7, 2026
- COURT-RULING reportJul 3, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 20, 2026
- 8-K reportApr 22, 2026
- PRESS-RELEASE reportApr 22, 2026
- 8-K reportApr 7, 2026
- CLUSTER reportMar 16, 2026
- CLUSTER reportMar 10, 2026
- 8-K reportFeb 24, 2026